Pick private label when the product concept already sells at retail and your edge is brand, channel or audience. Pick custom when the dose, active combination or sensory target is the product. The label, registration and notification rules are identical on both paths; only the development loops differ.
| Step | Private label | Custom |
|---|---|---|
| Feasibility | 3 to 5 business days: fit of existing concept | 3 to 5 business days: can the active load and taste be met |
| Formula work | Confirmation of chosen base, flavor, count | 2 to 4 weeks building the specification |
| Sample rounds | Usually one | Two or more, one variable per round |
| NDI risk (21 CFR 190.6) | Low with established ingredients | Present if a novel ingredient is chosen; 75 days |
| Pilot | 500 boxes | 500 boxes |
| Testing and documents | Same: 21 CFR 111.75 testing, batch record, Lot Release Packet | Same |
| Label and notification | Same: 21 CFR 101.36 and 101.93 | Same |
What each path actually is
Private label starts from an existing strip concept. You choose flavor and count, supply artwork, and the program moves through feasibility, a short confirmation of the chosen formula, sample sign-off, a 500-box pilot and release. The published phases still apply (feasibility 3 to 5 business days, formula work 2 to 4 weeks, iteration 1 to 3 weeks, pilot 2 to 4 weeks, testing and release about a week); what shrinks is the number of iteration rounds, because the starting point has already been made.
Custom starts from requirements: the active system, dose per serving, flavor, mouthfeel, dissolve target and the customer. The formulator is building the specification, so feasibility carries more weight. Film physics set the boundaries. Quick-release films run about 2 to 8 cm2 and 20 to 70 um, with active at 5 to 30 percent of dry weight (Palezi et al., 2023); polymer alone takes 45 to 65 percent of the strip (Irfan et al., 2016). Our development targets are a 22 x 32 mm strip, 50 to 150 um dry, 100 to 300 mg finished, up to about 250 mg single active, dissolving in 30 to 60 seconds.
Regulation does not care which path you took
Both paths land on the same rules, and all of them sit with the brand owner. The Supplement Facts panel follows 21 CFR 101.36. A structure/function claim requires FDA notification within 30 days of first marketing and the bold disclaimer under 21 CFR 101.93(c). Facility registration under 21 CFR 1.230 must exist before product is made or held, with renewal every even-numbered year between October 1 and December 31. FDA's 2010 compliance guide makes the own-label distributor responsible for knowing how the product was manufactured and for the release decision, on private label as much as on custom.
One rule bites custom harder. An ingredient not marketed in the United States before October 15, 1994 needs a new dietary ingredient notification 75 days before shipping under 21 CFR 190.6. A custom formula built around a novel botanical can add two and a half months that a private-label concept using established ingredients does not.
Decision rules
If the concept already exists at retail in your dose, go private label. A 5 mg melatonin strip in a 30-count box is sold under at least three brands on Amazon (NuStrips, EZStrip, Riize); a fourth wins on brand and channel, not on formula.
If your serving needs more than about 100 mg of active, or combines three or more actives, go custom; the taste and thickness tradeoffs are specific to that mix.
If your three non-negotiable attributes are all sensory (flavor, dissolve speed, no residue), start with a custom feasibility check even if you end up on a private-label base, because those attributes are set by the formula.
If you must launch inside one quarter, private label with established ingredients is the only path that avoids extra iteration rounds and the 75-day notification.
If the plan is a line of five products, run the first on private label to learn the channel, and reserve custom for the product where the formula is the story.
Two worked examples
Fernhill wants a 20 mg zinc-and-vitamin C strip, mint, 20-count, for a wellness subscription box. The concept and dose are conventional, the ingredients are established, the edge is the box's audience. Private label: feasibility, one confirmation round, sign-off, 500-box pilot of 10,000 strips plus about 300 for testing and reserves, release. Roughly 6 to 8 weeks inside the published range.
Orrin is a specialty coffee brand that wants a 200 mg combined caffeine, L-theanine and B-vitamin strip with a bitter-free finish and a dissolve under 45 seconds. Total active sits near the top of our 250 mg target, three actives interact, and the sensory targets are the product. Custom: feasibility, two to three formula rounds against written criteria, iteration, pilot, release, at the long end of the 6 to 10 week range, plus a longer active-supply lead time as the caffeine and L-theanine requirement grows with each reorder.
Compare the total path, not one milestone
Lay both routes out step by step: feasibility, formula work, iteration rounds, raw-material lead time, packaging print minimums, testing under 21 CFR 111.75, documentation, pilot, and the reorder trigger. Private label wins on early steps; custom can still win the launch if its formula sells through faster. The table shows where the two paths actually differ. Whichever you pick, we run the same 500-box pilot, standard release controls on every lot, third-party testing through ILS Lab and a Lot Release Packet per lot, because the release process does not know how the formula was chosen.
Common questions
It removes iteration rounds, not phases. Feasibility, pilot and release still run on the published timing. The gain is usually a few weeks, and it disappears if the private-label base needs a flavor change you keep revising.
Yes, and it is often the right order: learn the channel on a proven concept, then fund custom development for the product where the formula is the differentiator. Treat the switch as a new feasibility check, not an edit.
Only if it introduces an ingredient without pre-1994 U.S. market history, which triggers the 75-day notification under 21 CFR 190.6. Labeling, claims notification and facility registration are identical on both paths.
Primary sources
- Palezi S.C. et al., Oral disintegration films: applications and production methods, J Food Sci Technol 60(10):2539-2548 (2023)
- Irfan M. et al., Orally disintegrating films: a modern expansion in drug delivery system, Saudi Pharm J 24(5):537-546 (2016)
- 21 CFR 101.36, Supplement Facts labeling (Cornell LII)
- 21 CFR 101.93, Structure/function claims and disclaimer (Cornell LII)
- 21 CFR 1.230, Food facility registration and biennial renewal (Cornell LII)
- FDA Small Entity Compliance Guide to 21 CFR part 111 (Dec 2010)
- 21 CFR 190.6, New dietary ingredient 75-day notification (Cornell LII)
- 21 CFR 111.75, Testing of components and finished batches (Cornell LII)
- NuStrips 5 mg melatonin strips, 30 count (Amazon listing)
- EZStrip 5 mg melatonin / 10 mg L-theanine strips, 30 count (Amazon listing)
Formula feasibility, packaging, testing, claims, timing, and final quantities depend on the exact product. Use this guide to prepare better questions, then confirm the production plan for your project.